Literature DB >> 16884364

Arsenic trioxide exposure to ovarian carcinoma cells leads to decreased level of topoisomerase II and cytotoxicity.

N Askar1, T Cirpan, E Toprak, B Karabulut, N Selvi, M C Terek, R Uslu, U A Sanli, E Goker.   

Abstract

The objective of this study was to investigate the effect of arsenic trioxide (As(2)O(3)) on topoisomerase II levels using western blotting method on MDAH 2774 ovarian carcinoma cell culture. Experimental designs were established to determine the cytotoxic effects of As(2)O(3) on MDAH 2774 cells and the IC50 (fatal dose for the 50% of cells) value. Cytotoxicity experiments were carried out using various concentrations of As(2)O(3). The 2,3-bis[2-methyloxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide (XTT) and trypan blue dye-exclusion tests were used to evaluate cytotoxicity. Topoisomerase II expressions were investigated using western blotting method with various concentrations of As(2)O(3). Densitometric analysis of topoisomerase 2 bands was carried out using Quantity One 1-D analysis software (Bio-Rad USA, Life Science Research, Hercules, CA). IC50 value of As(2)O(3) was found to be 5 x 10(-6) M for MDAH 2774 cells. When the bands were evaluated, it was observed that there was a decrease in topoisomerase II levels in MDAH 2774 cells with increasing concentrations of As(2)O(3). It was also observed by the densitometric analysis that topoisomerase II expression ratios of MDAH 2774 cells were decreased by approximately 50% at this concentration. Topoisomerase II levels were significantly decreased with the increasing concentrations of As(2)O(3). Inhibition of topoisomerase II enzyme was one of the antiproliferative influence mechanisms of As(2)O(3).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16884364     DOI: 10.1111/j.1525-1438.2006.00626.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  2 in total

1.  Prognostic value of Holliday junction-recognizing protein and its correlation with immune infiltrates in lung adenocarcinoma.

Authors:  Long Chen; Chong Zeng; Limei Yan; Wanyu Liao; Chen Zhen; Jie Yao
Journal:  Oncol Lett       Date:  2022-05-27       Impact factor: 3.111

Review 2.  Current Treatments and New Possible Complementary Therapies for Epithelial Ovarian Cancer.

Authors:  Maritza P Garrido; Allison N Fredes; Lorena Lobos-González; Manuel Valenzuela-Valderrama; Daniela B Vera; Carmen Romero
Journal:  Biomedicines       Date:  2021-12-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.